Targeted Oncology1h
Oral Paclitaxel Outperforms IV in OS for Advanced Gastric Cancer
Oral paclitaxel matched IV in progression-free survival but outperformed it in overall survival for second-line advanced ...
Targeted Oncology17h
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...
Targeted Oncology19h
Primary Progressive Disease Rate Supports IO/TKI Use in Frontline mRCC
Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...
Targeted Oncology21h
FDA Grants FTD to 64Cu-SAR-bisPSMA for PET Imaging in Prostate Cancer
The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in ...